Gabather
0.7 SEK -5.41%1 investor is following this company
Gabather is a pharmaceutical company. Today, there is a business focus on developing drug candidates for the treatment of nerve diseases. Particular focus is on the stimulation of gamma-aminobutyric acid, which is the main inhibitory neurotransmitter in the brain. The drug candidates are today patented on a global level. Gabather was established in 2014 and is headquartered in Malmö.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
GABA
Daily low / high price
0.7 / 0.702
SEK
Market cap
26.44M SEK
Turnover
11.49K SEK
Volume
16K
Financial calendar
Interim report
29.08.2024
Interim report
28.11.2024
Annual report
27.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Avanza Pension | 14.4 % | 14.4 % |
Investment Aktiebolaget Balticum | 2.4 % | 2.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Gabather AB: Gabather files two new patent applications to secure novel findings on the effects of GT-002 for the treatment of psychiatric disorders
Gabather AB: Gabather reports initial positive results from the EEG/fMRI target engagement study
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools